Prospective, randomised, parallel-group, open-label study to evaluate the effectiveness and safety of IMU-838, in combination with oseltamivir, in adults with COVID-19: the IONIC trial protocol

BackgroundGlobally, there is a scarcity of effective treatments for SARS-CoV-2 infections (causing COVID-19). Repurposing existing medications may offer the best hope for treating patients with COVID-19 to curb the pandemic. IMU-838 is a dihydroorotate dehydrogenase inhibitor, which is an effective...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open 2022-11, Vol.12 (11), p.e055205-e055205
Main Authors: Sharma, Kavi, Berry, Lisa, Vryonis, Evangelos, Ali, Asad, Lara, Beatriz, Noufaily, Angela, Parsons, Nicholas, Bradley, Christopher, Haley, Becky, Tabuso, Maria, Arasaradnam, Ramesh P
Format: Article
Language:English
Subjects:
Antiviral drugs
Biosynthesis
Coronaviruses
COVID-19
Dehydrogenases
Fatalities
Hospitals
immunology
Infections
Infectious Diseases
Influenza
Inhibitor drugs
Intervention
Pandemics
public health
Severe acute respiratory syndrome coronavirus 2
Viral infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundGlobally, there is a scarcity of effective treatments for SARS-CoV-2 infections (causing COVID-19). Repurposing existing medications may offer the best hope for treating patients with COVID-19 to curb the pandemic. IMU-838 is a dihydroorotate dehydrogenase inhibitor, which is an effective mechanism for antiviral effects against respiratory viruses. When used synergistically with oseltamivir, therapeutic effects have been observed against influenza and SARS-CoV-2 in rodents. The IMU-838 and Oseltamivir in the Treatment of COVID-19 (IONIC) trial is a randomised controlled trial that will investigate whether time to clinical improvement in patients with COVID-19 is improved following a 14-day course of IMU-838+oseltamivir versus oseltamivir alone.MethodsIONIC trial is an open-label study in which participants will be randomised 1:1 in two parallel arms: the intervention arm (IMU-838+oseltamivir) and the control arm (oseltamivir only). The primary outcome is time to clinical improvement; defined as the time from randomisation to a two-point improvement on WHO ordinal scale; discharge from hospital, or death (whichever occurs first). The study is sponsored by the University Hospitals Coventry and Warwickshire NHS Trust and funded by LifeArc.DiscussionThe IONIC protocol describes an overarching trial design to provide reliable evidence on the effectiveness of IMU-838 (vidofludimus calcium) when delivered in combination with an antiviral therapy (oseltamivir) (IONIC intervention) for confirmed or suspected COVID-19 infection in adult patients receiving usual standard of care.Ethics and disseminationThis study has been independently reviewed and approved by Wales Research Ethics Committee. In addition, required regulatory approvals were received from Medicines and Healthcare products Regulatory Agency.Trial registration numberEudraCT 2020-001805-21, ISRCTN53038326, NCT04516915.
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2021-055205